# QUILT-3.055 (NCT03228667)

> QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03228667
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer
- Interventions: N-803 + Pembrolizumab; N-803 + Nivolumab; N-803 + Atezolizumab; N-803 + Avelumab; N-803 + Durvalumab; N-803 + Pembrolizumab + PD-L1 t-haNK; N-803 + Nivolumab + PD-L1 t-haNK; N-803 + Atezolizumab + PD-L1 t-haNK; N-803 + Avelumab + PD-L1 t-haNK; N-803 + Durvalumab + PD-L1 t-haNK; N-803 + Docetaxel + Pembrolizumab; N-803 + Docetaxel + Nivolumab
- Enrollment: 40
- Primary outcome: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.
- Primary outcome: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ

## Indexed commentary on QUILT-3.055 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=quilt-3-055-nct03228667